中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
24期
68-69,136
,共3页
舍曲林%喹硫平%强迫症%临床效果
捨麯林%喹硫平%彊迫癥%臨床效果
사곡림%규류평%강박증%림상효과
Sertraline%Quetiapine%Obsessive compulsive disorder%Clinical effect
目的:探讨舍曲林合并喹硫平治疗强迫症的疗效和安全性。方法选取我院在2012年12月~2013年6月中收治的强迫症患者100例,按照随机分配的原则分为治疗组和对照组,每组患者为50例。其中对照组患者采用舍曲林药物进行治疗,而治疗组患者采用舍曲林合并喹硫平进行治疗。治疗8周后对比两组患者临床疗效。结果经过治疗,两组患者的耶鲁布朗强迫量表、简明精神病评价量表以及汉密尔顿焦虑量表评分显著低于治疗前,且治疗组患者下降优于对照组,差异具有统计学意义(P<0.05)。结论对于强迫症患者采用舍曲林合并喹硫平治疗的效果好于单独使用舍曲林药物,值得在临床上广泛推广和应用。
目的:探討捨麯林閤併喹硫平治療彊迫癥的療效和安全性。方法選取我院在2012年12月~2013年6月中收治的彊迫癥患者100例,按照隨機分配的原則分為治療組和對照組,每組患者為50例。其中對照組患者採用捨麯林藥物進行治療,而治療組患者採用捨麯林閤併喹硫平進行治療。治療8週後對比兩組患者臨床療效。結果經過治療,兩組患者的耶魯佈朗彊迫量錶、簡明精神病評價量錶以及漢密爾頓焦慮量錶評分顯著低于治療前,且治療組患者下降優于對照組,差異具有統計學意義(P<0.05)。結論對于彊迫癥患者採用捨麯林閤併喹硫平治療的效果好于單獨使用捨麯林藥物,值得在臨床上廣汎推廣和應用。
목적:탐토사곡림합병규류평치료강박증적료효화안전성。방법선취아원재2012년12월~2013년6월중수치적강박증환자100례,안조수궤분배적원칙분위치료조화대조조,매조환자위50례。기중대조조환자채용사곡림약물진행치료,이치료조환자채용사곡림합병규류평진행치료。치료8주후대비량조환자림상료효。결과경과치료,량조환자적야로포랑강박량표、간명정신병평개량표이급한밀이돈초필량표평분현저저우치료전,차치료조환자하강우우대조조,차이구유통계학의의(P<0.05)。결론대우강박증환자채용사곡림합병규류평치료적효과호우단독사용사곡림약물,치득재림상상엄범추엄화응용。
Objective To discuss the efficacy and safety of sertraline combined with quetiapine in treatment of obsessive-compulsive disorder. Methods Selected 100 patients with OCD from Dec 2012 to Jun 2013 admitted to our hospital were divided into treatment group and control group according to the assigned randomly, each group with 50 cases. The control group was treated with sertraline, and the treatment group was treated with sertraline combined with quetiapine. After treatment of 8 weeks, the clinical efficacy between two groups was compared. Results After treatment, the Yale Brown Obsessive Compulsive Scale, the Brief Psychiatric Rating Scale and Hamilton Anxiety Scale score of two groups were significantly lower than those before treatment, and the patients in the treatment group were decreased more than control group, which was statistically significant (P<0.05). Conclusion Sertraline combined with quetiapine in treatment of obsessive-compulsive disorder shows better efficacy than sertraline alone, worthy of clinical promotion and application.